2013
DOI: 10.1016/j.antiviral.2013.05.002
|View full text |Cite
|
Sign up to set email alerts
|

Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
11
0

Year Published

2014
2014
2017
2017

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 23 publications
(14 citation statements)
references
References 27 publications
3
11
0
Order By: Relevance
“…These studies also suggested that 12 IU/ml is a more appropriate cutoff for response-guided treatment for a DAA-based triple therapy when the ART assay is used for HCV RNA quantification. Our results are also in line with the outcome of a similar study comparing the first-and second-generation Roche Cobas AmpliPrep/Cobas TaqMan HCV assays and the ART assay on samples from European and Japanese HCV genotype 1 patients treated with telaprevir-based therapy, respectively (23,26). In these studies, high correlation between the two assays and greater sensitivity of the ART assay were also observed.…”
Section: Discussionsupporting
confidence: 79%
See 1 more Smart Citation
“…These studies also suggested that 12 IU/ml is a more appropriate cutoff for response-guided treatment for a DAA-based triple therapy when the ART assay is used for HCV RNA quantification. Our results are also in line with the outcome of a similar study comparing the first-and second-generation Roche Cobas AmpliPrep/Cobas TaqMan HCV assays and the ART assay on samples from European and Japanese HCV genotype 1 patients treated with telaprevir-based therapy, respectively (23,26). In these studies, high correlation between the two assays and greater sensitivity of the ART assay were also observed.…”
Section: Discussionsupporting
confidence: 79%
“…Discordant results between the assays were mostly observed in samples with values bordering the LOQ and LOD. As previously reported, the ART assay demonstrated higher sensitivity for detection of the HCV load in the low range than the HPS assay (16,17,23). Overall, for 15% of patients who had no viral RNA detected by HPS, RNA was still detectable by ART.…”
Section: Discussionsupporting
confidence: 51%
“…Both ART and CAP/CTM can accurately predict the clinical outcomes of patients infected with HCV who received Peg-IFN-α2b/RBV [13] [14]. There have also been recent reports on CAP/CTM and ART for evaluating patients receiving TVR-based triple therapy [15] [16]. Although ART was better at detecting HCV RNA, in practice, CAP/CTM may be better at predicting non-SVR [15].…”
Section: Introductionmentioning
confidence: 99%
“…There have also been recent reports on CAP/CTM and ART for evaluating patients receiving TVR-based triple therapy [15] [16]. Although ART was better at detecting HCV RNA, in practice, CAP/CTM may be better at predicting non-SVR [15]. Another study found that ART assays performed at week 4 of treatment showed a higher positive predictive value (PPV) for the achievement of SVR at 24 weeks (SVR24) in patients receiving Peg-IFN α2a/RBV plus the protease inhibitors boceprevir or TVR than CAP/CTM [16].…”
Section: Introductionmentioning
confidence: 99%
“…Treatment with TPV, for example, should be discontinued at T12 week (T12w), if HCV RNA is >1,000 IU/ml at T12w [6,7]. Several studies underlined the importance of accurate quantification of the HCV RNA viral load when making decisions about shortening or extending treatment [89]…”
Section: Introductionmentioning
confidence: 99%